Yasemin Saplakoglu

The biotech company Moderna announced Monday (May 18) that their experimental coronavirus vaccine showed promising results in an early trial, known as a phase I study.

After receiving a single dose of the vaccine, called mRNA-1273, all 45 of the participants in the trial developed detectable levels of antibodies within 15 days, according to a statement from Moderna, which is based in Cambridge, Massachusetts. 



Source link